EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Activation of ERK1 /2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukaemia cells

Masanobu Tsubaki, Tomoya Takeda, Yuuichi Koumoto, Takehiro Usami, Takuya Matsuda, Shiori Seki, Kazuko Sakai, Kazuto Nishio, Shozo Nishida iD

Cell Proliferation · 2023

DOI: 10.1111/cpr.13420 ↗

At a glance

Journal article in Cell Proliferation, 2023. Written by Masanobu Tsubaki and 8 co-authors. Institution: Division of Pharmacotherapy, Kindai University School of Pharmacy, Higashi-Osaka, Osaka, Japan. Major MEDLINE topics: Fusion Proteins, bcr-abl, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Cited 4 times so far (Crossref); 28 references. The full text is freely available (open access, CC BY 4.0). Funded by: Japan Society for the Promotion of Science.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

The development of BCR::ABL1 tyrosine kinase inhibitors (TKIs), such as dasatinib, has dramatically improved survival in cases of chronic myeloid leukaemia (CML). However, the development of resistance to BCR::ABL1 TKIs is a clinical problem. BCR::ABL1 TKI resistance is known to have BCR::ABL1‐dependent or BCR::ABL1‐independent mechanisms, but the mechanism of BCR::ABL1 independence is not well understood. In the present study, we investigated the mechanism of BCR::ABL1‐independent dasatinib resistance. The expression and activation level of genes or proteins were evaluated using array CGH, real time PCR, or western blot analysis. Gene expression was modulated using siRNA‐mediated knockdown. Cell survival was assessed by using trypan blue dye method. We found that dasatinib‐resistant K562/DR and KU812/DR cells did not harbour a BCR::ABL1 mutation but had elevated expression and/or activation of MOS, TPL2 and ERK1/2. In addition, MOS siRNA, TPL2 siRNA and trametinib resensitized dasatinib‐resistant cells to dasatinib. Moreover, expression levels of MOS in dasatinib non‐responder patients with CML were higher than those in dasatinib responders, and the expression of TPL2 tended to increase in dasatinib non‐responder patients compared with that in responder patients. Our results indicate that activation of ERK1/2 by elevated MOS and TPL2 expression is involved in dasatinib resistance, and inhibition of these proteins overcomes dasatinib resistance. Therefore, MOS, TPL2 and ERK1/2 inhibitors may be therapeutically useful for treating BCR::ABL1‐independent dasatinib‐resistant CML.

Subjects

MeSH terms (MEDLINE)

Fusion Proteins, bcr-ablLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHumansDasatinibProtein Kinase InhibitorsMAP Kinase Signaling SystemDrug Resistance, Neoplasm

Substances

DasatinibFusion Proteins, bcr-ablProtein Kinase Inhibitors

Authors and institutions

  • Division of Pharmacotherapy, Kindai University School of Pharmacy, Higashi-Osaka, Osaka, Japan.
  • Department of Genome Biology, Kindai University School of Medicine, Osakasayama, Osaka, Japan.

ORCID profiles: Shozo Nishida

Funding

  • Japan Society for the Promotion of Science

Cite

APA

Tsubaki, M., Takeda, T., Koumoto, Y., Usami, T., Matsuda, T., Seki, S., Sakai, K., Nishio, K., & Nishida, S. (2023). Activation of ERK1 /2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukaemia cells. Cell Proliferation. https://doi.org/10.1111/cpr.13420

Vancouver

Tsubaki M, Takeda T, Koumoto Y, Usami T, Matsuda T, Seki S, et al. Activation of ERK1 /2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukaemia cells. Cell Proliferation. 2023. doi:10.1111/cpr.13420

BibTeX
@article{Tsubaki2023,
  author = {Tsubaki, Masanobu and Takeda, Tomoya and Koumoto, Yuuichi and Usami, Takehiro and Matsuda, Takuya and Seki, Shiori and Sakai, Kazuko and Nishio, Kazuto and Nishida, Shozo},
  title = {Activation of ERK1 /2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukaemia cells},
  journal = {Cell Proliferation},
  year = {2023},
  doi = {10.1111/cpr.13420}
}
Start for free →